SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs and Pharmaceuticals reports consolidated net profit of Rs 75.14 crore in Q4

27 May 2025 Evaluate

Akums Drugs and Pharmaceuticals has reported results for fourth quarter (Q4) and year ended March 31, 2025.

The company has reported net profit of Rs 27.59 crore for the quarter under review as compared to net loss of Rs 57.87 crore for the same quarter in the previous year. The total income of the company increased by 11.01% at Rs 360.80 crore for Q4FY25 as compared to Rs 325.02 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported net profit of Rs 75.14 crore for fourth quarter ended March 31, 2025 as compared to net loss of Rs 32.88 crore for the same quarter in the previous year. The total income of the company increased by 12.43% at Rs 1073.09 crore for Q4FY25 as compared to Rs 954.45 crore for the corresponding quarter previous year.

For the year ended March 31, 2025, the company has reported net profit of Rs 161.00 crore as compared to net loss of Rs 165.45 crore for the previous year. However, total income of the company decreased by 6.65% at Rs 1435.98 crore for year under review as compared to Rs 1538.24 crore for year ended March 31, 2024.

For the year ended March 31, 2025, on the consolidated basis, the company has reported net profit of Rs 345.25 crore as compared to net loss of Rs 45.28 crore for the previous year. However, total income of the company decreased by 1% at Rs 4170.28 crore for year under review as compared to Rs 4212.21 crore for year ended March 31, 2024.

Akums Drugs & Pharma Share Price

534.10 0.75 (0.14%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×